ReviewJournal of clinical medicine2021
Submassive Pulmonary Embolism: Current Perspectives and Future Directions.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Predictive accuracy of velocity time integral in predicting in-hospital outcomes in patients with intermediate-risk pulmonary embolism: a systematic review and meta-analysis.Internal and emergency medicine · 2025Pooled it
- Safety profile and resource utilisation associated with systemic alteplase versus unfractionated heparin in intermediate-high risk pulmonary embolism: a prospective ICU cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Refractory Hypoxemia as a Trigger for Systemic Thrombolysis in Intermediate-High-Risk Pulmonary Embolism: A Case Report.Reports (MDPI) · 2025Article
- Electrocardiographic Prediction of Acute Pulmonary Embolism at Intermediate-High- and High-Risk.Circulation reports · 2025Article
- Mechanical Thrombectomy and Catheter-Directed Lysis in Treating Intermediate-Risk Pulmonary Embolization: 30-Day Outcome.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Article
- Review
- Article
- Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives.Journal of clinical medicine · 2024Review
- Mechanical thrombectomy devices for the management of pulmonary embolism.JVS-vascular insights · 2024Article
- Characterizing the Spatiotemporal Transcriptomic Response of the Right Ventricle to Acute Pressure Overload.International journal of molecular sciences · 2023Article
- Contemporary management of intracardiac thrombi: a tale of two clots.The journal of extra-corporeal technology · 2023Review
- Left atrial mass found on cardiac ultrasound leading to emergent thrombectomy.Respiratory medicine case reports · 2023Article
- Intermediate-Risk Pulmonary Embolism: A Review of Contemporary Diagnosis, Risk Stratification and Management.Medicina (Kaunas, Lithuania) · 2022Review
- Pulmonary embolism in patients with severe COVID-19 treated with systemic low-dose thrombolytic therapy: A case series.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Submassive pulmonary embolism (PE) lies on a spectrum of disease severity between standard and high-risk disease. By definition, patients with submassive PE have a worse outcome than the majority of those with standard-risk PE, who are hemodynamically stable and lack imaging or laboratory features of cardiac dysfunction. Systemic thrombolytic therapy has been proven to reduce mortality in patients with high-risk disease; however, its use in submassive PE has not demonstrated a clear benefit, with haemodynamic improvements being offset by excess bleeding. Furthermore, meta-analyses have been confusing, with conflicting results on overall survival and net gain. As such, significant interest remains in optimising thrombolysis, with recent efforts in catheter-based delivery as well as upcoming studies on reduced systemic dosing. Recently, long-term cardiorespiratory limitations following submassive PE have been described, termed post-PE syndrome. Studies on the ability of thrombolytic therapy to prevent this condition also present conflicting evidence. In this review, we aim to clarify the current evidence with respect to submassive PE management, and also to highlight shortcomings in current definitions and prognostic factors. Additionally, we discuss novel therapies currently in preclinical and early clinical trials that may improve outcomes in patients with submassive PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.